MedTrace Logo

Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer

NCT05385185 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-05-23

No results posted yet for this study

Summary

immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe

Conditions

  • Leptomeningeal Metastasis
  • Immune Checkpoint Inhibitor
  • Endostatin

Interventions

DRUG

Camrelizumab or envafolimab

combine Camrelizumab or envafolimab with Recombinant human vascular endostatin

Sponsors & Collaborators

  • Hebei Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-01
Primary Completion
2024-05-03
Completion
2024-12-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05385185 on ClinicalTrials.gov